OMERS Administration Corp
ARTV icon

OMERS Administration Corp’s Artiva Biotherapeutics ARTV Stock Holding History

OMERS Administration Corp’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,400
Closed -$73.4K – 1163
2026
Q1 		$73.4K Sell
11,400
-9,700
-46% -$48K ﹤0.01% 1042
2025
Q4 		$90.5K Buy
+21,100
New +$79.7K ﹤0.01% 977

Other funds holding ARTV

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

OMERS Administration Corp's ARTV Position: Q2 2026 in Review

OMERS Administration Corp sold out of Artiva Biotherapeutics (ARTV) in Q2 2026, closing a stake of 11,400 shares — an estimated $73.4K sold.

OMERS Administration Corp first reported a position in ARTV in Q4 2025 and held it in 2 quarters. The position peaked at $90.5K in Q4 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • OMERS Administration Corp reported no remaining Artiva Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 11,400 Artiva Biotherapeutics shares in Q2 2026, an estimated $73.4K.
  • OMERS Administration Corp first reported a position in Artiva Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Artiva Biotherapeutics position peaked at $90.5K in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.